Active Immunotherapy for Lung Cancer
Author Information
Author(s): P.J. Lachmann, R.M. Grant, L.S. Freedman, K. Sikora, N.M. Bleehen
Primary Institution: Mechanisms in Tumour Immunity Unit, Clinical Oncology and Radiotherapeutics Unit & Ludwig Institute for Cancer Research MRC Centre
Hypothesis
Can a novel form of active immunotherapy improve outcomes in patients with squamous cell carcinoma of the lung?
Conclusion
The study suggests that the immunotherapy technique is harmless and may have some beneficial effects, but further research with larger patient numbers is needed.
Supporting Evidence
- The treatment was well tolerated with no significant adverse reactions.
- Survival rates were calculated using the actuarial method.
- Patients were followed up at regular intervals to monitor treatment response.
Takeaway
Doctors tried a new treatment for lung cancer that uses the patient's own tumor cells, and while it seemed safe, they need to test it on more people to see if it really helps.
Methodology
Patients with squamous cell carcinoma underwent surgery and received either surgery alone or surgery plus immunotherapy using their own tumor cells.
Limitations
The study involved a small number of patients, which limits the statistical significance of the findings.
Participant Demographics
Patients of either sex up to the age of 75 with histologically proven bronchial squamous carcinoma.
Statistical Information
P-Value
0.03
Confidence Interval
0.06 to 1.72
Want to read the original?
Access the complete publication on the publisher's website